

Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2020
Document Type: USP Monographs
DocId: GUID-A5639E2E-13B3-48B4-9C13-671BAC2ECBAA_3_en-US
DOI: https://doi.org/10.31003/USPNF_M31690_03_01
DOI Ref: 30tbq

© 2025 USPC
Do not distribute

Ethosuximide Oral Solution

DEFINITION

Ethosuximide Oral Solution contains NLT 90.0% and NMT 105.0% of the labeled amount of ethosuximide ($C_7H_{11}NO_2$).

IDENTIFICATION

Change to read:

- A. **▲SPECTROSCOPIC IDENTIFICATION TESTS (197), Infrared Spectroscopy: 197S** ▲ (CN 1-May-2020)

Standard solution: 30.0 mg/mL of [USP Ethosuximide RS](#) in [chloroform](#)

Sample solution: Nominally 30 mg/mL of ethosuximide in [chloroform](#) prepared as follows. Transfer the equivalent of about 150 mg of ethosuximide from Oral Solution to a 125-mL separatory funnel, add 50 mL of [ether](#), and shake well. Allow the layers to separate, and retain the ether layer. Wash the ether layer with three 10-mL portions of [water](#). Transfer the ether layer to a suitable beaker, add 5 g of [anhydrous sodium sulfate](#), and swirl. Filter the mixture into a 50-mL volumetric flask through a small pledget of cotton that has been previously washed with [ether](#). Evaporate to dryness. Dissolve the residue in 5 mL of [chloroform](#).

Wavelength range: 3000–1650 cm^{-1}

Analysis

Samples: Standard solution and Sample solution

Acceptance criteria: Meets the requirements

- B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

Change to read:

• PROCEDURE

Mobile phase: [Acetonitrile](#) and [water](#) (12.5:87.5). To each liter, add 1.0 mL of [glacial acetic acid](#).

System suitability solution: 0.062 mg/mL of [USP Ethosuximide RS](#) and 0.064 mg/mL of [2-ethyl-2-methylsuccinic acid](#) in Mobile phase

Standard solution: 0.062 mg/mL of [USP Ethosuximide RS](#) in Mobile phase

Sample solution: Nominally 0.062 mg/mL of ethosuximide from Oral Solution in Mobile phase prepared as follows. Transfer a volume of Oral Solution, equivalent to 250 mg of ethosuximide, to a 100-mL volumetric flask. Dilute with Mobile phase to volume. Transfer 5.0 mL of this solution to a 200-mL volumetric flask and dilute with Mobile phase to volume.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 225 nm

Column: 3.9-mm × 15-cm; ▲4- μm ▲ (USP 1-May-2019) packing L1

Flow rate: 1 mL/min

Injection volume: 10 μL

▲Run time: NLT 2 times the retention time of ethosuximide ▲ (USP 1-May-2019)

System suitability

Sample: System suitability solution

▲[Note—The relative retention times for ethosuximide and 2-ethyl-2-methylsuccinic acid are 1.0 and 1.3, respectively.] ▲ (USP 1-May-2019)

Suitability requirements

Resolution: NLT 3.5 between ethosuximide and 2-ethyl-2-methylsuccinic acid

Tailing factor: NMT 1.5

Relative standard deviation: NMT ▲1.0% ▲ (USP 1-May-2019) for ethosuximide and NMT 5.0% for 2-ethyl-2-methylsuccinic acid

Analysis

Samples: Standard solution and Sample solution

Calculate the percentage of the labeled amount of ethosuximide ($C_7H_{11}NO_2$) in the portion of Oral Solution taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_U = peak response from the *Sample solution* r_S = peak response from the *Standard solution* C_S = concentration of [USP Ethosuximide RS](#) in the *Standard solution* (mg/mL) C_U = nominal concentration of ethosuximide in the *Sample solution* (mg/mL)**Acceptance criteria:** 90.0%–105.0%**IMPURITIES**• **LIMIT OF 2-ETHYL-2-METHYLSUCCINIC ACID****Mobile phase, System suitability solution, Chromatographic system, and System suitability:** Proceed as directed in the Assay.**Standard solution:** 0.05 mg/mL of [2-ethyl-2-methylsuccinic acid](#) in *Mobile phase***Sample solution:** Nominally 2.5 mg/mL of ethosuximide from Oral Solution in *Mobile phase* prepared as follows. Using a “to contain” pipet, transfer a volume of Oral Solution, equivalent to 250 mg of ethosuximide, to a 100-mL volumetric flask. Rinse the pipet several times with *Mobile phase*, and dilute with *Mobile phase* to volume.**Analysis****Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of 2-ethyl-2-methylsuccinic acid in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

 r_U = peak response of 2-ethyl-2-methylsuccinic acid from the *Sample solution* r_S = peak response of 2-ethyl-2-methylsuccinic acid from the *Standard solution* C_S = concentration of 2-ethyl-2-methylsuccinic acid in the *Standard solution* (mg/mL) C_U = nominal concentration of ethosuximide in the *Sample solution* (mg/mL)**Acceptance criteria:** NMT 2.0%**SPECIFIC TESTS**• [pH \(791\)](#): 4.5–5.8**ADDITIONAL REQUIREMENTS****Change to read:**• **PACKAGING AND STORAGE:** Preserve in tight containers. ▲Store at controlled room temperature. Protect from freezing and light. ▲ (USP 1-May-2019)• [USP Reference Standards \(11\)](#).[USP Ethosuximide RS](#)**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
ETHOSUXIMIDE ORAL SOLUTION	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 44(1)

Current DocID: GUID-A5639E2E-13B3-48B4-9C13-671BAC2ECBAA_3_en-US**DOI:** https://doi.org/10.31003/USPNF_M31690_03_01**DOI ref:** [30tbq](#)